Wild-type ATTR (ATTRwt)/Systemic senile amyloidosis
Dec 10, 2015
Background:
Heart failure caused by wild-type transthyretin amyloidosis (ATTRwt) is an underappreciated cause of morbidity and mortality in the aging population.…
Apr 21, 2013
BACKGROUND:
Cardiac amyloidosis is a fatal disease whose prognosis and treatment rely on identification of the amyloid type. In our aging population transthyretin…
Non-Liver Transplant Therapies for ATTR Amyloidosis 2022 lists different medications and therapies for treating ATTR Amyloidosis, a genetic disorder characterized…
Please join us on January 21st, 2023 from 12:00 pm - 3:00 pm ET for our next webinar on ATTRv and ATTRwt Amyloidosis. Our speakers include Cardiologist Mathew…
The treatment uses CRISPR/Cas9 editing technology, a technique derived from bacteria that allows researchers to edit the genome of a cell by specifying regions of…
Investigators have found that intravenous infusion of a CRISPR-Cas9 based gene therapy decreases serum transthyretin (TTR) protein in patients with hereditary TTR…
Researchers from Intellia Therapeutics, Regeneron Pharmaceuticals, and clinical partners have published the first-ever clinical data that support the safety and…
People with hereditary transthyretin (ATTR) amyloidosis have a mutation in the transthyretin (TTR) gene, which means they produce an abnormal protein that gradually…
The gene editor CRISPR excels at fixing disease mutations in lab-grown cells. But using CRISPR to treat most people with genetic disorders requires clearing an…
Preliminary results from a landmark clinical trial suggest that CRISPR-Cas9 gene editing can be deployed directly into the body to treat disease.
The study is the…